Treatment strategies for DNA repair-deficient prostate cancer.

ABSTRACT:

Introduction

Common recurrent genetic alterations have been identified in prostate cancer through comprehensive sequencing efforts, and the prevalence of mutations in DNA repair pathway genes in patients with advanced and metastatic disease approaches 20-25%. Identification of these underlying DNA repair defects may present unique treatment opportunities for patients, both in terms of standard-of-care treatments and selected investigational agents. Areas covered: We review our current understanding of the genomic landscape of prostate cancer, with special attention to alterations in DNA repair pathway genes in metastatic castration-resistant disease. For patients with tumors deficient in homologous recombination repair, potential opportunities for treatment include platinum chemoth

SUBMITTER: Teply BA 

PROVIDER: S-EPMC6088808 | biostudies-literature | 2017 Aug

REPOSITORIES: biostudies-literature